Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology; D001581:Benzothiadiazines; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects; D004232:Diuretics; D004347:Drug Interactions; D005464:Fluorobenzenes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D011453:Prostaglandins / Q000652:urine; D012459:Salicylates / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology; D013997:Time Factors; D014527:Uric Acid / Q000652:urine
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D001581:Benzothiadiazines; D001786:Blood Glucose; D004232:Diuretics; D005464:Fluorobenzenes; D007004:Hypoglycemic Agents; D011453:Prostaglandins; D012459:Salicylates; D049993:Sodium Chloride Symporter Inhibitors; D014527:Uric Acid